Combination therapy increased M1/M2 ratio in TAMs (tumor-associated macrophages), decreased the expression of PD-L1 and promoted the recruitment of activated CD8+ T cells in the TME (tumor microenvironment). The gene discussed is CD8A; the disease is neoplasm.